Advanced Search

Oncology & Hematology Coding Alert

Learn More about Blinatumomab

Published on Fri Apr 17, 2015

On December 3, 2014, the U. S. Food and Drug Administration granted approval for blinatumomab (Blincyto™) for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL). However, the FDA will continue to assess the clinical benefits in future trials to sustain the approval in this indication.  What is blinatumomab? Blinatumomab is a T-cell engager. [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All